0RV2 Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 226.79 |
| 52 Week High | SEK 248.20 |
| 52 Week Low | SEK 137.90 |
| Beta | -0.26 |
| 1 Month Change | 9.14% |
| 3 Month Change | 61.84% |
| 1 Year Change | 10.07% |
| 3 Year Change | 108.45% |
| 5 Year Change | 178.62% |
| Change since IPO | 739.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RV2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 2.7% | -3.2% | 1.0% |
| 1Y | 10.1% | -19.7% | 12.1% |
Return vs Industry: 0RV2 exceeded the UK Biotechs industry which returned -19.7% over the past year.
Return vs Market: 0RV2 underperformed the UK Market which returned 12.1% over the past year.
Price Volatility
| 0RV2 volatility | |
|---|---|
| 0RV2 Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RV2's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RV2's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 104 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
| 0RV2 fundamental statistics | |
|---|---|
| Market cap | SEK 19.78b |
| Earnings (TTM) | -SEK 232.86m |
| Revenue (TTM) | SEK 167.14m |
118.4x
P/S Ratio-84.9x
P/E RatioIs 0RV2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RV2 income statement (TTM) | |
|---|---|
| Revenue | SEK 167.14m |
| Cost of Revenue | SEK 90.50m |
| Gross Profit | SEK 76.64m |
| Other Expenses | SEK 309.50m |
| Earnings | -SEK 232.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 45.85% |
| Net Profit Margin | -139.32% |
| Debt/Equity Ratio | 0% |
How did 0RV2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 03:16 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioArctic AB (publ) is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Rajan Sharma | Goldman Sachs |